Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | SELP | P16109 | 7/20 | 0.49 |
| ▸ | SELL | P14151 | 3/20 | 0.49 |
| ▸ | SELE | P16581 | 3/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14477842 | 1.00 | APP (0.50) | APPSELPSELLSELECETP | |
| SCHEMBL14477841 | 1.00 | APP (0.50) | APPSELPSELLSELECETP | |
| SCHEMBL20786854 | 1.00 | APP (0.50) | APPSELPSELLSELECETP | |
| SCHEMBL20786855 | 1.00 | APP (0.50) | APPSELPSELLSELECETP | |
| SCHEMBL20676799 | 0.92 | APP (0.51) | APPSELPSELLSELEEPHX2 | |
| SCHEMBL20676876 | 0.92 | APP (0.51) | APPSELPSELLSELEEPHX2 | |
| SCHEMBL20676797 | 0.92 | APP (0.51) | APPSELPSELLSELEEPHX2 | |
| SCHEMBL20676875 | 0.92 | APP (0.51) | APPSELPSELLSELEEPHX2 | |
| SCHEMBL14477826 | 0.91 | SELP (0.43) | APPSELPSELLSELECETP | |
| SCHEMBL14477832 | 0.90 | SELP (0.43) | APPSELPSELLSELECETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853173-B2 | Synthetic glycolipid and use thereof | RIKEN (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20130005669-A1 | NOVEL SYNTHETIC GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005669-A1 | NOVEL SYNTHETIC GLYCOLIPID AND USE THEREOF | IFNG, IFNAR1, UGCG | APP 4110/4885SELP 1317/4885SELL 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.